We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Herbalife (HLF) Stock Up on Better-than-Expected Q1 Earnings
Read MoreHide Full Article
Shares of Herbalife Ltd. (HLF - Free Report) gained 4.5% in after-hours trading on May 4 after the nutritional-products company posted better-than-expected earnings and revenues in the first quarter 2017 and issued an upbeat 2017 outlook.
Quarter in Detail
This weight management company delivered fourth-quarter adjusted earnings of $1.24 per share, which beat the Zacks Consensus Estimate of 87 cents by 42.5%. Earnings were within the management’s guided range of 85 cents to $1.05 per share. Adjusted earnings, however, declined 8.1% year over year due to a 10 cents negative impact from currency.
Net sales of $1.10 billion declined 2% from the prior-year period but the decline was narrower than the guided range of a decline of 5% to 9%. This was the second consecutive quarter of sales decline, after three consecutive quarters of growth in revenues. Currency had a neutral impact on sales in the quarter. Sales also beat the Zacks Consensus Estimate of $1.04 billion by 5.9%.
Sales volume increased 1% in the quarter, up from the expected range of down 1–5%. We note that sales and volumes in China significantly exceeded expectations primarily due to the positive timing of sales and volume resulting from a price increase announced in Mar 2017. As a result, member purchases shifted into the first quarter instead of the second quarter of this year.
Regionally, China recorded growth of 17%, followed by 5% growth in each Asia Pacific and Europe, the Middle East and Africa (EMEA) regions and 4% volume growth in Mexico. Volume growth in Mexico represented the sixth straight quarter of volume growth. However, volume points for South & Central America declined 14% due to weakness in Brazil, while North America witnessed a decline of 5%.
Herbalife’s shares have surged 29.2% on a year-to-date basis, higher than the Zacks categorized Retail-Drug Stores industry’s dip of 0.2%.
Other Financial Update
Herbalife ended the quarter with cash and cash equivalents of $1.78 billion, long-term debt of $2.19 billion, and total shareholders’ equity of $267.4 million.
During the quarter, the company generated cash flow from operations of $175.5 million and incurred capital expenditure of $24.5 million.
In the quarter, the company repurchased 2.1 million shares for $119 million and has approximately $1.38 billion remaining under the new program.
For full-year 2017, management raised its earnings and sales outlook on the back of upbeat first quarter results. The company now expects adjusted earnings in the range of $4.05−$4.45, up from $3.65−$4.05 per share expected earlier. However, the new guidance is still lower than the 2016 adjusted earnings of $4.85 per share. This includes currency impact of 20 cents, compared with 50 cents expected earlier. On a currency adjusted basis, earnings are expected in a range of $4.25–$4.65 per share, compared with $4.20–$4.60 anticipated earlier.
Herbalife now expects sales to grow in a range of 3.0–6.0%, higher from 0.3–3.3% expected earlier. Volumes are expected to increase 2.0–5.0% in 2017. On a currency adjusted basis, sales are expected to increase 3.6–6.6%.
Q2 Guidance
Herbalife expects sales to fall in the range of 0.5–4.5% due to a decline in volume of 1–5% in the second quarter. On a currency adjusted basis, sales are expected in the range of flat to a decline of 4.0%.
For second-quarter 2017, the company expects adjusted earnings per share to grow in the range of 85 cents–$1.05 per share, which includes an unfavorable currency impact of approximately 4 cents per share. Excluding the currency impact, adjusted earnings are expected in a range of 88 cents–$1.08 per share.
Rocky Brands posted a positive surprise of 42.9% in the preceding quarter. While Children’s Place has expected long-term earnings growth of 8.00%, Wal-Mart has expected long-term earnings growth of 6.1% for the next three to five years.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Herbalife (HLF) Stock Up on Better-than-Expected Q1 Earnings
Shares of Herbalife Ltd. (HLF - Free Report) gained 4.5% in after-hours trading on May 4 after the nutritional-products company posted better-than-expected earnings and revenues in the first quarter 2017 and issued an upbeat 2017 outlook.
Quarter in Detail
This weight management company delivered fourth-quarter adjusted earnings of $1.24 per share, which beat the Zacks Consensus Estimate of 87 cents by 42.5%. Earnings were within the management’s guided range of 85 cents to $1.05 per share. Adjusted earnings, however, declined 8.1% year over year due to a 10 cents negative impact from currency.
Net sales of $1.10 billion declined 2% from the prior-year period but the decline was narrower than the guided range of a decline of 5% to 9%. This was the second consecutive quarter of sales decline, after three consecutive quarters of growth in revenues. Currency had a neutral impact on sales in the quarter. Sales also beat the Zacks Consensus Estimate of $1.04 billion by 5.9%.
Sales volume increased 1% in the quarter, up from the expected range of down 1–5%. We note that sales and volumes in China significantly exceeded expectations primarily due to the positive timing of sales and volume resulting from a price increase announced in Mar 2017. As a result, member purchases shifted into the first quarter instead of the second quarter of this year.
Regionally, China recorded growth of 17%, followed by 5% growth in each Asia Pacific and Europe, the Middle East and Africa (EMEA) regions and 4% volume growth in Mexico. Volume growth in Mexico represented the sixth straight quarter of volume growth. However, volume points for South & Central America declined 14% due to weakness in Brazil, while North America witnessed a decline of 5%.
Herbalife’s shares have surged 29.2% on a year-to-date basis, higher than the Zacks categorized Retail-Drug Stores industry’s dip of 0.2%.
Other Financial Update
Herbalife ended the quarter with cash and cash equivalents of $1.78 billion, long-term debt of $2.19 billion, and total shareholders’ equity of $267.4 million.
During the quarter, the company generated cash flow from operations of $175.5 million and incurred capital expenditure of $24.5 million.
In the quarter, the company repurchased 2.1 million shares for $119 million and has approximately $1.38 billion remaining under the new program.
Herbalife LTD. Price, Consensus and EPS Surprise
Herbalife LTD. Price, Consensus and EPS Surprise | Herbalife LTD. Quote
Full-Year 2017 Guidance Raised
For full-year 2017, management raised its earnings and sales outlook on the back of upbeat first quarter results. The company now expects adjusted earnings in the range of $4.05−$4.45, up from $3.65−$4.05 per share expected earlier. However, the new guidance is still lower than the 2016 adjusted earnings of $4.85 per share. This includes currency impact of 20 cents, compared with 50 cents expected earlier. On a currency adjusted basis, earnings are expected in a range of $4.25–$4.65 per share, compared with $4.20–$4.60 anticipated earlier.
Herbalife now expects sales to grow in a range of 3.0–6.0%, higher from 0.3–3.3% expected earlier. Volumes are expected to increase 2.0–5.0% in 2017. On a currency adjusted basis, sales are expected to increase 3.6–6.6%.
Q2 Guidance
Herbalife expects sales to fall in the range of 0.5–4.5% due to a decline in volume of 1–5% in the second quarter. On a currency adjusted basis, sales are expected in the range of flat to a decline of 4.0%.
For second-quarter 2017, the company expects adjusted earnings per share to grow in the range of 85 cents–$1.05 per share, which includes an unfavorable currency impact of approximately 4 cents per share. Excluding the currency impact, adjusted earnings are expected in a range of 88 cents–$1.08 per share.
Zacks Rank and Key Picks
Herbalife carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the retail sector are Rocky Brands, Inc. (RCKY - Free Report) , The Children’s Place, Inc. (PLCE - Free Report) and Wal-Mart Stores, Inc. (WMT - Free Report) . While both Rocky Brands and Children’s Place hold a Zacks Rank #1 (Strong Buy), Wal-Mart carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Rocky Brands posted a positive surprise of 42.9% in the preceding quarter. While Children’s Place has expected long-term earnings growth of 8.00%, Wal-Mart has expected long-term earnings growth of 6.1% for the next three to five years.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>